Development of a platform to non-invasively assess microvascular endothelial dysfunction at the bedside in covid-19 patients throughout intensive care

Ended Project Grant Awarded Last action

Award ID
R21EB031261
Recipient
Awarding agency
Obligated
$385,726

Award facts

Completion date
Originally
Place of performance
Dallas, TX 75390, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
/project summary the worldwide covid-19 pandemic has caused over 430,000 deaths (june 2020) and generated an acute need for point-of-care technologies to assess patients infected with sars-COV-2. Endothelial dysfunction is a common complication of covid-19, leading to strokes, acute coronary syndrome, and thrombotic events. These sequelae are mediated by decreased microvascular function. Microvascular dysfunction is a common pathway to end organ injury in a variety of pathophysiologies, including acute respiratory distress syndrome (ARDS) and sepsis. Currently, ~35-62% of covid-19 patients with ARDS who receive respiratory support do not survive. Microvascular function is not routinely assessed during critical care. Thus, understanding of injury mechanisms and development of potential therapeutics are limited by a critical GAP in knowledge due to inadequate methods. Our team has recently carried out a pilot study to assess microvascular health in covid- 19 patients, demonstrating the feasibility of this technique under highly demanding clinical conditions. In aim 1 of this project, we will develop and test a platform combining state-of-the-art near-infrared and diffuse correlation spectroscopies into an integrated remotely controlled system to monitor microvascular blood volume, oxygen saturation, and flow during vascular occlusion. This comprehensive data set, not possible to obtain with current commercial devices, will enable the separation between deficiencies in oxygen delivery and oxygen utilization. In aim 2, we will demonstrate the usability of our platform during critical care under infection-control precautions in ARDS patients with and without covid-19. This non-invasive assessment of microvascular health will allow serial monitoring of patients, enabling assessment of the efficacy of interventions and disease progression. Such a device can readily be translated to other diagnoses: any disease or trauma which causes microvascular dysfunction, including shock and diabetic vasculopathy, could potentially be assessed with the platform we will develop. If successful, the work of this interdisciplinary team of physical scientists and clinicians will establish the feasibility of serially assessing microvascular health during critical illness. These results will in able future development of hemodynamic monitoring tools and algorithms to support management of ARDS and intensive care unit patients, ultimately reducing mortality and morbidity.

Transactions

Action Obligated Date
Amendment $0
Amendment $0
Amendment $0
Original award $385,726

Subawards

Subrecipient Amount Awarded
Institut De Ciencies Fotoniques (Icfo) ICFO is a world leader in developing and translating optical technologies to measure deep tissue blood flow. Until very recently, devices which can measure ~1cm… $171,495

Quick answers

Who received award R21EB031261?

R21EB031261 was awarded to The University Of Texas Southwestern Medical Center by National Institute of Biomedical Imaging and Bioenginering (National Institutes of Health) on June 30, 2021.

How much is award R21EB031261 worth?

$385,726 has been obligated on R21EB031261.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login